Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Lipton

Showing results (1041-1050 of 1,173) with videos related to

Pageof 118
Sort By:
JAMA Network Open|June 8, 2022
Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical TrialRichard B Lipton, Patricia Pozo-Rosich, Andrew M Blumenfeld, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|May 31, 2008
Adiponectin levels and genotype: a potential regulator of life span in humansGil Atzmon, Toni I Pollin, Jill Crandall, et al.
Pediatric Diabetes|July 30, 2008
Diagnosis and treatment of neonatal diabetes: a United States experienceJulie Støy, Siri Atma W Greeley, Veronica P Paz, et al.
Brain, Behavior, & Immunity - Health|March 4, 2022
Individuals with both higher recent negative affect and physical pain have higher levels of C-reactive proteinJennifer Graham-Engeland, Natasha N DeMeo, Dusti R Jones, et al.
Neurology. Clinical Practice|September 6, 2021
Response to Mindfulness-Based Cognitive Therapy Differs Between Chronic and Episodic MigraineElizabeth K Seng, Alexandra B Conway, Amy S Grinberg, et al.
The Lancet. Neurology|October 4, 2015
Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b studyMarcelo E Bigal, Lars Edvinsson, Alan M Rapoport, et al.
Headache|February 1, 2017
Psychological Factors Associated With Chronic Migraine and Severe Migraine-Related Disability: An Observational Study in a Tertiary Headache CenterElizabeth K Seng, Dawn C Buse, Jaclyn E Klepper, et al.
Archives of Clinical Neuropsychology : the Official Journal of the National Academy of Neuropsychologists|December 3, 2014
Neurocognitive function among middle-aged and older Hispanic/Latinos: results from the Hispanic Community Health Study/Study of LatinosHector M González, Wassim Tarraf, Natalia Gouskova, et al.
The Lancet. Neurology|October 10, 2014
Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trialDavid W Dodick, Peter J Goadsby, Stephen D Silberstein, et al.
Headache|October 5, 2023
Plasma calcitonin gene-related peptide and nerve growth factor as headache and pain biomarkers in recently deployed soldiers with and without a recent concussionAnn I Scher, James S McGinley, Lyndsey R VanDam, et al.
Pageof 118

Showing results (1041-1050 of 1,173) with videos related to

Sort By:
Pageof 118
JAMA Network Open|June 8, 2022
Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical TrialRichard B Lipton, Patricia Pozo-Rosich, Andrew M Blumenfeld, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|May 31, 2008
Adiponectin levels and genotype: a potential regulator of life span in humansGil Atzmon, Toni I Pollin, Jill Crandall, et al.
Pediatric Diabetes|July 30, 2008
Diagnosis and treatment of neonatal diabetes: a United States experienceJulie Støy, Siri Atma W Greeley, Veronica P Paz, et al.
Brain, Behavior, & Immunity - Health|March 4, 2022
Individuals with both higher recent negative affect and physical pain have higher levels of C-reactive proteinJennifer Graham-Engeland, Natasha N DeMeo, Dusti R Jones, et al.
Neurology. Clinical Practice|September 6, 2021
Response to Mindfulness-Based Cognitive Therapy Differs Between Chronic and Episodic MigraineElizabeth K Seng, Alexandra B Conway, Amy S Grinberg, et al.
The Lancet. Neurology|October 4, 2015
Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b studyMarcelo E Bigal, Lars Edvinsson, Alan M Rapoport, et al.
Headache|February 1, 2017
Psychological Factors Associated With Chronic Migraine and Severe Migraine-Related Disability: An Observational Study in a Tertiary Headache CenterElizabeth K Seng, Dawn C Buse, Jaclyn E Klepper, et al.
Archives of Clinical Neuropsychology : the Official Journal of the National Academy of Neuropsychologists|December 3, 2014
Neurocognitive function among middle-aged and older Hispanic/Latinos: results from the Hispanic Community Health Study/Study of LatinosHector M González, Wassim Tarraf, Natalia Gouskova, et al.
The Lancet. Neurology|October 10, 2014
Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trialDavid W Dodick, Peter J Goadsby, Stephen D Silberstein, et al.
Headache|October 5, 2023
Plasma calcitonin gene-related peptide and nerve growth factor as headache and pain biomarkers in recently deployed soldiers with and without a recent concussionAnn I Scher, James S McGinley, Lyndsey R VanDam, et al.
Pageof 118